SCHEMBL23568153

SCHEMBL23568153

CN(C(=O)OC(C)(C)C)[C@H]1CC[C@H](CCN)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.39
JAK2 O60674 1/20 0.37
JAK1 P23458 1/20 0.37
JAK3 P52333 1/20 0.37
ASGR1 P07306 1/20 0.35
KAT6A Q92794 1/20 0.35
KAT8 Q9H7Z6 1/20 0.35
LSS P48449 3/20 0.34
NR1H2 P55055 1/20 0.32
ACACB O00763 1/20 0.31
ACACA Q13085 1/20 0.31
ALDH1A1 P00352 1/20 0.31
KMT2A Q03164 1/20 0.31
PIK3CD O00329 1/20 0.31
KDM4D Q6B0I6 1/20 0.31
DPP4 P27487 1/20 0.30
DPP8 Q6V1X1 1/20 0.30
DPP9 Q86TI2 1/20 0.30
DPP7 Q9UHL4 1/20 0.30
HTR2A P28223 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23696903 1.00 HSD11B1 (0.39) HSD11B1JAK2JAK1JAK3ASGR1
SCHEMBL23539527 1.00 HSD11B1 (0.39) HSD11B1JAK2JAK1JAK3ASGR1
SCHEMBL21996669 0.89 HSD11B1 (0.40) HSD11B1JAK2JAK1JAK3ASGR1
SCHEMBL23696268 0.89 HSD11B1 (0.40) HSD11B1JAK2JAK1JAK3ASGR1
SCHEMBL22849379 0.89 HSD11B1 (0.40) HSD11B1JAK2JAK1JAK3ASGR1
SCHEMBL7817060 0.86 HSD11B1 (0.40) HSD11B1JAK2JAK1JAK3ASGR1
SCHEMBL25731984 0.85 HSD11B1 (0.34) HSD11B1JAK2JAK1JAK3ASGR1
SCHEMBL190837 0.85 HSD11B1 (0.47) HSD11B1JAK2JAK1JAK3ASGR1
SCHEMBL24448742 0.84 HSD11B1 (0.40) HSD11B1JAK2JAK1JAK3ASGR1
SCHEMBL23696267 0.84 NR1H2 (0.43) HSD11B1JAK2JAK1JAK3ASGR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11779578-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-10-10 US disclosed
US-11779578-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-10-10 US disclosed
US-11707457-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-07-25 US disclosed
US-11707457-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-07-25 US disclosed
US-20230144292-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-05-11 US disclosed
US-20230144292-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-05-11 US disclosed
US-20210228562-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2021-07-29 US disclosed
WO-2021127190-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210228562-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 HSD11B1 2834/4885JAK2 184/4885JAK1 165/4885
US-11779578-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 HSD11B1 2834/4885JAK2 184/4885JAK1 165/4885
US-11707457-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 HSD11B1 2834/4885JAK2 184/4885JAK1 165/4885
US-20230144292-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 HSD11B1 2834/4885JAK2 184/4885JAK1 165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.